Complex Regional Pain Syndrome (CRPS) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Complex Regional Pain Syndrome (CRPS) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The complex regional pain syndrome market is expected to register a CAGR of 2.1% over the forecast period.

The complex regional pain syndrome market has been significantly impacted by the COVID-19 pandemic, particularly in its early stages. COVID-19 infection causes peripheral nerve lesions, including small fiber neuropathy. The potentially disabling complication of any peripheral nerve lesion is complex regional pain syndrome (CRPS). For instance, a study report titled "Complex regional pain syndrome after severe COVID-19 – A case report" published in November 2021 stated that the systemic hyperinflammation in severe COVID-19 may contribute to peripheral and central neuronal sensitization, which may increase the risk of developing complex regional pain syndrome (CRPS). As a result of the COVID-19 effect on neuronal sensitization, the demand for drugs used in complex regional pain had witnessed a positive impact. Thus, the impact of COVID-19 on the market was adverse in its initial stages owing to supply chain constraints. However, owing to the aforesaid instances, the demand for CRPS drugs is likely to grow in the near future.

The major growth drivers of the complex regional pain syndrome market over the forecast period are the rising incidence of complex regional pain syndrome and the growing number of patients suffering from chronic pain. For instance, as per the study titled "A Comprehensive Review on Neuroplastic Changes Supporting the Use of Non-invasive Neurostimulation in Clinical Settings" published in September 2021, the worldwide prevalence of complex regional pain syndrome varies from 5.5 to 26.2 per 100,000 people per year. Also, as per the report titled "A Korean nationwide investigation of the national trend of complex regional pain syndrome vis-à-vis age-structural transformations" published in July 2021, the general CRPS incidence rate was 15.83 per 100,000, with 19.5 for type 1 and 12.1 for type 2. Also, the increase in chronic pain among patients influences the market growth. For instance, as per the report titled "The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis" published in September 2021, the prevalence of pain is 60%, 48% for chronic pain, and 10% for neuropathic pain among chronic kidney disease patients. Thus, with the significantly high incidence rate and increase of chronic pain among patients, the demand for complex regional pain syndrome drugs is expected to increase, which is anticipated to have a positive impact on the growth of the studied market during the forecast period.

However, a lack of awareness about the target disease in developing countries is expected to restrain the complex regional pain syndrome market during the forecast period.

Key Market TrendsSpinal Cord Stimulation Segment is Expected to Dominate the Market During the Forecast Period

A spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain. As CRPS involves severe chronic pain, a spinal cord stimulator is effective and safe with minimal to no side effects in relieving the pain of CRPS. The spinal cord stimulation segment is expected to witness significant growth over the forecast period owing to factors such as increasing cases of chronic pain and increasing adoption of technologically advanced products.

The rising prevalence of drug resistance among patients with chronic pain leads to increasing cases of complications in patients. For instance, as per the report titled "Spinal cord stimulation in chronic pain: technical advances" published in April 2020, the prevalence of drug resistance for certain groups of pain syndromes is higher, like chronic pelvic pain, where it is 20%–65%, and in patients with chronic neuropathic pain after spinal cord injury, it is 96%. Thus, a growing prevalence of drug increases the cases of chronic pain and is likely to increase the demand for spinal cord stimulation.

New product approvals and launches under this segment drive the growth of the market segment further. For instance, in January 2022, Nevro Corp received approval for expanded labeling for its Senza Spinal Cord Stimulation (SCS) System from the United States Food and Drug Administration for the treatment of Non-Surgical Refractory Back Pain (NSRBP).

Therefore, due to the above-mentioned factors, the spinal cord stimulation market segment is expected to grow over the forecast period of the study.

North America is Expected to Hold a Significant Share in the Market During the Forecast Period

North America is expected to hold a major market share in the complex regional pain syndrome market. The primary factors behind the large market size are the rising prevalence of complex regional pain syndrome and high public and private healthcare spending, which are stimulating the growth of the region. Moreover, easy access to quality healthcare, favorable reimbursement policies, a strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America. According to the study report titled "Canadian surveillance study of complex regional pain syndrome in children" published in June 2022, the minimum Canadian incidence of complex regional pain syndrome is estimated at 1.14 per 100,000 children per year, and the highest among girls 12 years and older at 3.10 per 100,000. Thus, the high incidences of complex regional pain syndrome will drive the market during the study period.

New product approvals and launches will drive the growth of the complex regional pain syndrome market further. For instance, in August 2022, Abbott received approval from the United States Food and Drug Administration for its new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy, which provides tailored relief to multiple pain areas and adds more treatment options for evolving pain conditions.

Thus, the increasing cases of complex regional pain syndrome, and increasing company activities in the region are expected to augment the market growth over the forecast period.

Competitive Landscape

The complex regional pain syndrome market is slightly fragmented in nature due to the presence of several companies operating globally. The major players include Abbott., Boston Scientific Corporation, GSK plc, ICU Medical, Johnson & Johnson Services, Inc., Medtronic, Viatris Inc, Nevro Corp., Purdue Pharma, and Sanofi. The players operating in the market focus on introducing new products to address the changing need of the patients.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.